Frontiers in Urology

OCT 8, 2026 · JOURNAL ARTICLE

Longitudinal CT-derived muscle–fat–bone remodeling following androgen deprivation therapy initiation in prostate cancer

Frontiers in Urology

Introduction Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment and is commonly accompanied by longitudinal changes in muscle, adipose tissue, and ske

SEP 7, 2026 · JOURNAL ARTICLE

Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer

Frontiers in Urology

A retrospective single-centre analysis of metastasis-directed SBRT in oligo-recurrent prostate cancer showing feasible local control and delayed systemic therapy, but lacking a comparator and prospective design.

SEP 2, 2026 · JOURNAL ARTICLE

Gut microbes and benign prostatic hyperplasia: the role of dysbiosis

Frontiers in Urology

A narrative review synthesizing emerging preclinical and associative clinical evidence for a putative gut–prostate axis in BPH, acknowledging that current evidence remains largely mechanistic and associative with few direct human studies.

AUG 17, 2026 · REVIEW

Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis

Frontiers in Urology

Rigorous systematic review and meta-analysis of 13 studies showing SRT+ADT improves biochemical progression-free survival and metastasis-free survival with low heterogeneity, though overall survival benefit remains uncertain.

AUG 7, 2026 · JOURNAL ARTICLE

Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy

Frontiers in Urology

Retrospective cohort study with propensity matching showing mortality and renal benefits of GLP-1RA versus comparators in a specific high-risk population, but limited by observational design, potential unmeasured confounding, and modest event numbers acknowledged by authors.